Date
Attendees
Committee Member | Present | Absent |
---|---|---|
X | ||
Amy Leblanc | X | |
X | ||
X | ||
X | ||
Debbie Knapp | X | |
Toby Hecht | X | |
Ralph Parchment | X |
Goals
- Discuss updates to ICDC and define emerging strategies and priorities
SharePoint Site
https://nih.sharepoint.com/sites/NCI-CBIIT-FNL-ICDC-ICDCLeadershipGroups
Outstanding Action Items
- Kuffel, Gina (NIH/NCI) [C] to relay info to Debbie for cancer types of interest to request from FidoCure: Glioma, osteosarcoma, bladder cancer, mucosal and acral melanoma, mast cell tumor. Request overview of what they have in their DB.
- Debbie to write invitation for Jaime Modiano
- Revisit new steering committee members in September
Agenda
Item | Who | Talking Points |
---|---|---|
Continue discussion of potential submission of FidoCure Animal Health data | Sommers, Connie (NIH/NCI) [E] Debbie Knapp |
|
DGAB Updates | Recently Approved
ICDC Studies in Active Submission
| |
BPSC Updates |
| |
Upcoming Steering Committee Meeting | Ralph Parchment |
|
Minutes (Not Verbatim)
CS- At minimum we are interested in genomic data and clinical metadata as represented on the ICDC.
TH - Series biopsy information as well.
EK - Sam from UChicago Data for the Common Good is aware of the ICDC and there are comparative studies of interest between canine and pediatric cancer.
Previous ICDC Use Cases from Steering Committee
1. Genomic correlates across platforms (DNA, RNA, protein).
2. Correlating multi-omics data with clinical annotation and phenotypes, particularly outcomes.
3. Comparative analyses of canine and human. Examples include:
1. Search for conserved mutations between canine and human tumors
2. Disease diagnosis (e.g. cancer type) and classification mapping between canines and humans
5. Gene expression changes and mutational profiles associated with therapeutic response and outcome
6. How do sporadic tumors in non-human mammals compare to sporadic human tumors?
7. Correlations and model building from radiomic and pathomic features extracted from medical and histopathologic images with outcomes and genomics, as is currently being widely done with human images
8. Develop biomarkers of response and resistance in humans by analyzing the responses and genomic signatures in dogs.
Action items
- Kim, Erika (NIH/NCI) [E] to email Sam V and Nicky Mason about a cross-species collaboration.
- Kuffel, Gina (NIH/NCI) [C] to email Ralph about changing the date of the upcoming Steering Committee.